Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.
Eshaitan - I’m now at the point where there is no option to sell, might as well ride it out. He has promised so much and delivered so little. Some will say have
patience, we’re not at the end of Q1 yet, but we all know the timeline will slip again at that stage.The company will be transformed by then apparently, well he has certainly done that with the share price. At £30k per month remuneration there is no urgency to move things along and forget share bonus milestones, we’re a world away from that. Let’s not forget that he has a very small stake in the company share wise and these were grudgingly purchased a couple of years ago when there was a lot of noise at the time of the placing at 16p. He could of course buy some more now and hopefully lift the price a little but does he have the confidence, at 9p it’s pocket change?
I don’t doubt that the products work but two years plus down the line from the Axis ‘soft’ launch have we lost the market because I’m sure Del Boy could sell more from the local market stall?
I really want this to work because there are undoubtedly benefits to people who actually suffer from the ailments Skin is targeting but how much longer are we going to be told ‘this can’t be discussed because it’s sensitive’ or ‘we have no control over this, it’s a PLC that keeps things close’ or ‘discussions continue with multi nationals’.
I think we have been failed by the management, it’s obvious the market has no confidence in them and I have certainly lost faith.
S it possible that increased Axisbiotix sales have contributed to the apparent reduced cash burn figure?
Just a thought having read a two star Trustpilot review submitted in early August but held pending whilst this was challenged but subsequently posted in late September. This was the only review on Trustpilot submitted by someone called ‘Mateo’ although I have my suspicions this is a pseudonym for someone called ‘The Dictator’ who will be well known to others on this board.
The Axisbiotix team countered with a response which finished with ‘If you read many of our other reviews you will see that the product has worked extremely well for thousands of our customers’. Maybe just an error/overstatement but I would have thought that given the nature of the review, any response from the team would be checked and thoroughly vetted before being posted,
I may be well off the mark here but Stuart did say in the latest interview with Elrico that Axisbiotix retention rates were exceptionally good.
Interesting indeed - depressing certainly. I’m struggling to take one positive from the report. Is there a multi national interested or not - I certainly don’t want to hear in another six months or so that no progress has been made on this front. Croda - should get revenue in 2023, I don’t like the word ‘should’ it doesn’t breed confidence. Beyond that nothing definitive on the other pillars and then a placing at current market price or more realistically given the timing of the release a premium after tomorrows likely rout of the share price.
Belgrano - totally agree, your statement is short and straight to the point. Months since anything official from the company. We know the results already it’s the update that’s important. What company holds back good news? I’m convinced the results and update will be released very late next week just before markets close for the holiday- this in my opinion can only mean one thing.
Aqua - excellent post. I don’t have access to the Q&As so only know what has been commented on following its issue. I like to think this makes me an unbiased observer - the one big ‘take’ I have from your comment is the possibility of results being released after markets close on the 23rd - it’s a ‘red flag’ to me, purely my opinion but if they are good SBTX would be issuing asap not hiding them over the Christmas period. I hope I’m proved wrong.
Clio - totally agree. It’s the first time I’ve felt disappointed with Stuart.
The lack of information imparted to shareholders directly is becoming a source of irritation. I don’t think it’s too much to ask for a full, frank and truthful picture of the company and it’s strategy.
The cryptic comments are already being bandied around - suffice to say the garden wall is far too high for me to see if there is any grass whatever colour it is on the other side.
All things aside, we’re invested to grow our ‘hard earned’ and there is precious little at the moment to give confidence.
More 5 star reviews added today.
There is a one star review posted today, 5 hours ago relating to non receipt of order. What I like is that Axis responded immediately (5hours ago) to say they have e mailed the customer twice and also tried to ring them more than once. This is great service!
I think the message is getting out there and it can only help sales via repeat orders and recommendations.
Phat - I have to agree. My hopes in the shorter term are also pinned on the Croda pillar. Axis created some froth last year but at the moment I’m not convinced this is going to take the share price back to the heady levels seen 12 months ago, certainly in the medium term, so we need another source to do this. The product obviously works and there’s even evidence the blend actually improves other conditions - some good reviews of late on Trustpilot evidence this too. I’m just not convinced the influencers are a) good enough b) have the clout to get this moving and c) we don’t appear to be getting the hits (see Facebook for some particularly woeful ‘like’ and ‘view’ numbers). I know some will say this needs time but the spectre of Opti looms large and I don’t want Skin to be another ‘manana’ share - I’m too old for that!
Is it time to look at alternatives with Axisbiotix? It’s clear that with current funding and staff levels it’s stretching everyone and maybe it needs a bigger partner to get this in front of people and also ease the burden on Stuart and the team. B2C cuts out the middleman but do we have the resources to exploit this? I believe in Axis and every time I listen to Stuart he inspires confidence in me.
I’m not a big investor (just over 40,000 shares) but I still think this has potential to be one of my better investments. If I’m being truly mercenary, I’d probably take an offer (at the right price) from a major player but putting this aside, it would be a shame because of all the hard work Stuart and the team have invested. This has potential to be a solid business and also offer the potential of a life changing product for people who are currently unaware of Axisbiotix - we just need to get this to their attention - we owe it to them.
I’m no expert - just my own personal thoughts!
Wac
It is relentless at the moment - strange pattern, as Bel says, a raft of small sells in the low thousands, then the larger trade just after hours. Also, a number of very low sells (15,16,17 shares) which has been a feature over the past few days almost as if trying to manipulate the number of sell trades.
Almost at the stage where they will have flushed out the weak holders and everyone else will be sitting tight.
I remain invested - I trust Stuart, the Axisbiotix product works, Croda should bring good news and the other three pillars are progressing nicely according to updates.
Just a shame that Skin is listed on the AIM cesspit but we all know how sentiment can shift quickly. I’m holding for better days.
‘Disappointing’ would be the launch being a total flop but we keep being told it’s early days and I agree, it is just that. The only doubt I have is that someone is privy to inside information because selling has been relentless. I keep telling myself that the company has a good product, needs time and if we can get the Croda launch up and running the last few days will just be a blip. The only niggle I have with this is that we don’t seem to have definite dates for Croda and it does seem to just keep trundling along. This share has been heavily ramped on this board but I don’t think that this would really have any material impact upon the shares as a whole. We all know investing is about timing and it can just as easily swing back with just a little bit of good news - hell we need it at the moment though! GLA
I think you did the right thing in selling. I reduced my holding mid year and have just watched this fall continuously since then. Communication continues to be a bone of contention with this company and I agree, as a shareholder why can’t I get information and updates without a third party input - it appears that anything positive (if there is actuallly anything) is classed as price sensitive so can’t be disclosed but this has been going on forever. Are we ever going to see the supposed potential this company had or is it just ‘froth’? Call me cynical but strangely enough, when Opti sold the last batch of SBTX, price sensitivity didn’t appear to be an issue looking at the recent trashing of the SBTX share price subsequent to this.
Traintracks - ‘interesting’ one this. Integumen has changed its name but prior to this had the ticker name SKIN. If you now type SKIN into the search facility it brings up Skinbiotherapeutix (SBTX). It must be an anomaly and whoever is responsible for website content at SBTX should have picked this up. Strange though how it can still generate a stock price for Integumen?
Clio - In fairness though at the time of the quote it was registration only. Interested to see the next update from SBTX. Some very good buying this afternoon after a very quiet spell, maybe there will be news next week.
He was a blatant ramper - supposedly introducing an institution via his business who were going to invest on a large scale. He gave himself away early on when he claimed to be in for the long term - a month or so later he was back on the board saying he had bought back in. Assume he sold out just before the news dropped never to be heard of again - won’t be missed.